(Q36292466)

English

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90) (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

breast carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Pierga JY

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Jouve M

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Asselain B

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Livartowski A

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Beuzeboc P

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Diéras V

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Scholl S

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Dorval T

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Palangié T

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Garcia-Giralt E

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Pouillart P

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

1 May 1998

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

77

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1474-1479

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1998.242

0 references

Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

30 September 2017

Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

30 September 2017

Infusional cancer chemotherapy: historical evolution and future development at the Cancer Center of Boston

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

30 September 2017

Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

30 September 2017

Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

30 September 2017

5-Fluorouracil by Protracted Venous Infusion: A Review of Recent Clinical Studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

30 September 2017

FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

30 September 2017

Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

29 June 2018

Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

29 June 2018

Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

29 June 2018

Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

29 June 2018

A scale of valuations of states of illness: is there a social consensus?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

29 June 2018

Multivariate analysis of prognostic factors in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150182

22 September 2018

Phase I study of protracted venous infusion of 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved survival of patients with metastatic breast cancer receiving combination chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous 5-fluorouracil infusion in refractory carcinoma of the breast

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Metastatic breast cancer. Chemotherapy with adriamycin, vindesine, cyclophosphamide and 5 FU. Value of continuous 5 FU perfusion. Results of controlled trials]

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of adjuvant systemic therapy on response to treatment after relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/9652764

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1998.242

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36292466&oldid=1584667742"